» Articles » PMID: 25818738

Advances in Tumor Markers of Ovarian Cancer for Early Diagnosis

Overview
Journal Indian J Cancer
Specialty Oncology
Date 2015 Mar 31
PMID 25818738
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer often occurs in perimenopausal women. The mortality of ovarian cancer is in the first place among gynecological cancers because of no obvious early symptoms and the lack of effective diagnostic approach. Gene chips, proteomics, immunohistochemistry and other methods have become hot topics for early diagnosis of ovarian cancer. However, due to the variety of pathology and not clear enough of mechanism and etiology, there is still no ideal tumor markers with both high specific and sensitivity, which can be applied into clinical early diagnosis for ovarian cancer. Therefore, a new systematic method with high sensitivity and specificity for early diagnosis of ovarian cancer and new tumor markers need to be identified. We should make an examination of ovarian cancer in the early period in the crowd for early diagnosis and early treatment to further improve life quality of patients. This paper reviewed the recent advancements of tumor markers for early diagnosis of ovarian cancer.

Citing Articles

Clinical effects of IPCH after the surgery for ovarian cancer at the middle or advanced stage and its impacts on tumor markers and immune functions.

Li H, Zhang Y, Tang H, Li L Pak J Med Sci. 2024; 40(9):1919-1924.

PMID: 39416607 PMC: 11476136. DOI: 10.12669/pjms.40.9.8720.


Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer.

Utkarsh K, Kumar A, Aditi , Khan A, Nayyar A, Haque S Genes Dis. 2023; 10(3):1005-1018.

PMID: 37396515 PMC: 10308119. DOI: 10.1016/j.gendis.2022.07.004.


Comprehensive Analysis Identifies the PPAR-Targeted Genes Associated with Ovarian Cancer Prognosis and Tumor Microenvironment.

Leng X, Wang G, Yin H, Wei F, Zeng K, Zhang Y PPAR Res. 2023; 2023:6637414.

PMID: 37213709 PMC: 10195182. DOI: 10.1155/2023/6637414.


CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer.

Hu P, Lei L, Wang Y, Tian X, Wei X, Jiang N Mediators Inflamm. 2023; 2023:1075265.

PMID: 37057131 PMC: 10089777. DOI: 10.1155/2023/1075265.


SPOCK1 Overexpression Suggests Poor Prognosis of Ovarian Cancer.

Vancza L, Horvath A, Seungyeon L, Rokusz A, Dezso K, Reszegi A Cancers (Basel). 2023; 15(7).

PMID: 37046698 PMC: 10093273. DOI: 10.3390/cancers15072037.